Laffer Tengler Investments’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-11
Closed -$11.6K – 314
2024
Q2
$11.6K Hold
11
– – ﹤0.01% 307
2024
Q1
$10.6K Hold
11
– – ﹤0.01% 299
2023
Q4
$9.66K Hold
11
– – ﹤0.01% 272
2023
Q3
$9.05K Sell
11
-2,443
-100% -$1.92M ﹤0.01% 281
2023
Q2
$1.76M Sell
2,454
-52
-2% -$40.1K 0.47% 73
2023
Q1
$2.06M Buy
2,506
+86
+4% +$64.9K 0.56% 68
2022
Q4
$1.75M Buy
2,420
+90
+4% +$66.4K 0.5% 66
2022
Q3
$1.61M Buy
2,330
+43
+2% +$27.1K 0.59% 69
2022
Q2
$1.35M Sell
2,287
-43
-2% -$28K 0.47% 82
2022
Q1
$1.63M Sell
2,330
-43
-2% -$27.2K 0.49% 81
2021
Q4
$1.5M Buy
2,373
+266
+13% +$164K 0.43% 89
2021
Q3
$1.28M Buy
2,107
+411
+24% +$255K 0.37% 103
2021
Q2
$947K Buy
1,696
+1,269
+297% +$643K 0.36% 93
2021
Q1
$202K Buy
427
+47
+12% +$22.9K 0.08% 154
2020
Q4
$182K Buy
+380
New +$205K 0.08% 160
2016
Q2
– Sell
-4,353
Closed -$1.57M – 258
2016
Q1
$1.57M Buy
+4,353
New +$1.79M 0.42% 111
2015
Q4
– Hold
0
– – – 42
2015
Q3
– Sell
-4,353
Closed -$2.34M – 48
2015
Q2
$2.22M Buy
+4,353
New +$2.12M 0.54% 42

Other funds holding REGN

Laffer Tengler Investments's REGN Position: Q3 2024 in Review

Laffer Tengler Investments sold out of Regeneron Pharmaceuticals (REGN) in Q3 2024, closing a stake of 11 shares — an estimated $11.6K sold.

Laffer Tengler Investments first reported a position in REGN in Q2 2015 and held it in 17 quarters. The position peaked at $2.22M in Q2 2015. 1,392 funds tracked by Wall St. Rank hold REGN as of Q3 2024.

  • Laffer Tengler Investments reported no remaining Regeneron Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Laffer Tengler Investments sold 11 Regeneron Pharmaceuticals shares in Q3 2024, an estimated $11.6K.
  • Laffer Tengler Investments first reported a position in Regeneron Pharmaceuticals in Q2 2015 and held it in 17 quarters.
  • Laffer Tengler Investments's Regeneron Pharmaceuticals position peaked at $2.22M in Q2 2015.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2024.

Based on Laffer Tengler Investments's 13F filing for Q3 2024, filed 4 Nov 2024.